Oxytocin is a mammalian neurohypophysial hormone which stimulates uterine contraction and lactation.

LIT-001 is the first nonpeptide oxytocin receptor agonist.

PF-3274167 is a high-affinity nonpeptide oxytocin receptor (OTR) antagonist, with Ki of 9.5 nM.

Oxytocin acetate is a mammalian neurohypophysial hormone and its actions are mediated by specific, high-affinity oxytocin receptors and ligand of oxytocin receptor.

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. In addition, atosiban suppresses oxytocin-mediated release of PGE and PGF from the decidua. In human pre-term labor, atosiban, at the recommended dosage, antagonizes uterine contractions and induces uterine quiescence. The onset of uterus relaxation following atosiban is rapid, uterine contractions being significantly reduced within 10 minutes to achieve stable uterine quiescence.

Atosiban is competitive antagonist of vasopressin and oxytocin receptors. It is a nonapeptide and the analogue of desamino-oxytocin.

Lysipressin is an antidiuretic hormone that havs been found in pigs and some marsupial families. It can induce contraction of the rabbit urinary bladder smooth muscle.

L-368,899 HCl is a potent, selective, orally bioavailable, non-peptide oxytocin receptor antagonist, with IC50s of 8.9 nM and 26 nM for rat uterus and human uterus oxytocin receptor, respectively, used as a tocolytic agent.

OT-R antagonist 1 is a potent and selective nonpeptide low molecular weight OT-R antagonist.

SHR1653 is a highly potent oxytocin receptor antagonist with excellent blood-brain barrier penetration. It might be beneficial for the treatment of CNS-related premature ejaculation.

OT antagonist 1 (Compound 4) is a potent, selective Oxytocin antagonist with a Ki of 50 nM.

Retosiban is an oral active, potent and selective, sub-nanomolar (Ki = 0.65 nM) oxytocin receptor antagonist with > 1400-fold selectivity over the related vasopressin receptors. Retosiban inhibits the procontractile effect of stretch on human myometrium and prevent stretch-induced stimulation of human myometrial contractility.

GSK 557296 is a potent, selective and orally bioavailable oxytocin receptor antagonist, with a pKi of 9.9 for human oxytocin receptor.

OT-R antagonist 2 is a nonpeptide low molecular weight OT-R antagonist.

OT antagonist 3 is an oxytocin (OT) antagonist extracted from patent WO2007017752A1.

Carbetocin is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth and an agonist at peripheral oxytocin receptors.

Carbetocin is an obstetric drug used to control postpartum hemorrhage and bleeding after giving birth and an agonist at peripheral oxytocin receptors.